PGT121.414.LS
Phase 2Small molecule
PGT121.414.LS is one of 76 small molecule programs targeting HIV. It is currently in Phase 2.
4
Indications
8
Total Trials
5
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
66 competitors in HIV-1 Infection
#DrugCompanyPhaseTrials
1Tybost
GileadApproved
Renvela
SanofiApproved
Emtriva
GileadApproved
Vemlidy
GileadApproved
Taxol
TevaApproved
Cabenuva
GSKApproved
Niacor
AbbVieApproved
Epidiolex
Jazz PharmaceuticalsApproved
Oncovin
Eli LillyApproved
Crestor
AstraZenecaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
HIV2 trials
Phase I/II Trial to Evaluate the Impact of Three Broadly Neutralizing Antibodies or Analytic Treatment Interruption on Viral Reservoir, Immune Function, and Maintenance of HIV Suppression in Early Treated Children in Botswana
Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT06508749·41 enrolled
A Randomized, Double Blind, Controlled, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Neutralization of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV
Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06812494·200 enrolled
Clinical Trial1 trial
HIV-1 infection1 trial
A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection
Not yet recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT06987318·40 enrolled
Monoclonal1 trial
Intravenous1 trial
Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT04212091·33 enrolled
2 more indications
HIV-11 trial
Acute HIV Infection1 trial
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05719441·48 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PGT121.414.LS. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details